Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Muscle-invasive Bladder Cancer × tremelimumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Hepatocellular 19 Colorectal Neoplasms 8 Carcinoma, Non-Small-Cell Lung 8 Squamous Cell Carcinoma of Head and Neck 5 Melanoma 5 Prostatic Neoplasms 4 Mesothelioma, Malignant 4 Liver Neoplasms 4 Cholangiocarcinoma 4 Biliary Tract Neoplasms 4 Urinary Bladder Neoplasms 3 Neoplasms 3 Neoplasm Metastasis 3 Head and Neck Neoplasms 3 Fallopian Tube Neoplasms 3 Diabetes Mellitus, Insulin-Dependent, 12 3 Stomach Neoplasms 2 Ovarian Neoplasms 2 Neoplasms, Germ Cell and Embryonal 2 Mesothelioma 2 Lung Neoplasms 2 Gallbladder Neoplasms 2 Carcinoma, Renal Cell 2 Breast Neoplasms 2 Adenocarcinoma Of Esophagus 2 Vascular Neoplasms 1 Uveal Melanoma 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1

Interventions

tremelimumab 1 pembrolizumab 1 enfortumab vedotin 1 durvalumab 1 Watchful Waiting 1 Radiotherapy 1 Palliative Care 1 Drug Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03234153 2020-06-17

NITIMIB

Insel Gruppe AG, University Hospital Bern

Phase 2 Terminated

Muscle-invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡